|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dave Watrous says a strong training roadmap for digital literacy begins at the top, and it begins far in advance of any major Artificial Intelligence or Machine Learning project rollouts.
|
|
|
Pedro Moura Alves, PhD, reviews the intricacies of AhR immune sensing and signaling, and its potential for personalized treatment strategies to optimize therapeutic outcomes and minimize adverse effects. He also touches on some of the limitations hindering the advancement of knowledge in this crucial area of research, and the direction this emerging field may take in the coming years.
|
|
|
Matt Clark, PhD, explores DEL’s application in three areas of drug discovery that have received much attention throughout the past 5 years: Induced Proximity, Covalent Drug Discovery, and Machine Learning.
|
|
|
David A. Katz, PhD, and Robert Jacks, MBA, MSE, say a new, effective treatment option is now available, promotion of the drug will increase disease awareness, and the success encourages others in the industry to continue and expand their PMR research. However, the proportion of patients who can benefit from the drug is limited, and significant unmet needs remain for all persons suffering from PMR.
|
|
|
Yoon-Tae Kang, PhD, Abiodun Bodunrin, PhD, and Joby Chesnick, PhD, MBA, believe co-analysis of CTC abundance and phenotypic changes together with ctDNA concentration could allow for real-time monitoring of disease progression and reoccurrence, while genetic and epigenetic changes in CTCs and ctDNA mutations over time could provide valuable insights into the effectiveness of therapeutic interventions, as the presence of different somatic mutations may indicate cancer susceptibility or resistance to certain treatments.
|
|
|
|
|
|
|
|
|

Mikron Automation is your worldwide partner for advanced assembly solutions. Our solutions are reliable and tailored to complex products. At Mikron we are committed to delivering the best assembly systems and services throughout the product’s entire life cycle. With our extensive engineering expertise, scalable platforms, and lifelong support, we ensure the success of our clients. With more than 4,000 assembly and test systems in use worldwide, our team has unique process expertise and the rigor for complex project management in a wide range of industries. Click here for more.
|
|
|
|
|
|
 |
|
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
|
|
 |
|
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….
|
|
 |
|
Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over 3 years….
|
|
 |
|
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication….
|
|
|
|
|
|
|
|
 |
|
Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.
CLICK HERE TO DOWNLOAD/VIEW THE …
|
|
 |
|
The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …
|
|
 |
|
Peptide therapeutics are a hot topic in pharmaceutical R&D. While most peptides are administered parenterally, oral delivery of peptide therapeutics offers several advantages. Enteris BioPharma’s latest whitepaper outlines the key parameters that drug developers should considering while evaluating oral delivery …
|
|
 |
|
Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …
|
|
|
|
|
Upcoming eNewsletter Features:
May 1 – Nasal Drug Delivery
May 8 – Capsules
|
|
|
|
|
|
|
|